Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Merit Medical Systems (MMSI)

Merit Medical preliminary 2024 revenue $1.355 billion to $1.357 billion, up 7.7%-7.9%

Positive Impact 3 of 5 earnings Written later

Merit Medical said preliminary unaudited revenue for the year ended December 31, 2024 is about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% from the prior year. The figures are unaudited and may change after the audit, and the company plans to report full fourth-quarter and 2024 results and 2025 guidance on February 25, 2025.

Key points

  • Preliminary 2024 revenue of about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% year over year
  • Preliminary constant currency revenue increased about 8.4% to 8.6%; the foreign exchange impact is $7.9 million
  • Audited results are not yet available, and the auditor has not reviewed the preliminary figures
  • Full 2024 results and fiscal 2025 guidance are scheduled for February 25, 2025 after market close

The filing

CompanyMerit Medical Systems (MMSI)
Form8-K, current report
Filed with the SECJan 13, 2025, 8:12 PM ET
Accession number0000856982-25-000003

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.